Success Metrics

Clinical Success Rate
87.5%

Based on 42 completed trials

Completion Rate
88%(42/48)
Active Trials
5(7%)
Results Posted
31%(13 trials)
Terminated
6(9%)

Phase Distribution

Ph phase_1
5
7%
Ph phase_3
9
13%
Ph phase_2
21
31%
Ph not_applicable
8
12%
Ph phase_4
19
28%
Ph early_phase_1
2
3%

Phase Distribution

7

Early Stage

21

Mid Stage

28

Late Stage

Phase Distribution64 total trials
Early Phase 1First-in-human
2(3.1%)
Phase 1Safety & dosage
5(7.8%)
Phase 2Efficacy & side effects
21(32.8%)
Phase 3Large-scale testing
9(14.1%)
Phase 4Post-market surveillance
19(29.7%)
N/ANon-phased studies
8(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.8%

42 of 52 finished

Non-Completion Rate

19.2%

10 ended early

Currently Active

5

trials recruiting

Total Trials

67

all time

Status Distribution
Active(7)
Completed(42)
Terminated(10)
Other(8)

Detailed Status

Completed42
unknown8
Terminated6
Withdrawn4
Recruiting4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
67
Active
5
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.1%)
Phase 15 (7.8%)
Phase 221 (32.8%)
Phase 39 (14.1%)
Phase 419 (29.7%)
N/A8 (12.5%)

Trials by Status

active_not_recruiting11%
enrolling_by_invitation11%
unknown812%
withdrawn46%
terminated69%
not_yet_recruiting11%
completed4263%
recruiting46%

Recent Activity

Clinical Trials (67)

Showing 20 of 67 trialsScroll for more
NCT07430046Phase 2

Repurposing Mirtazapine in Rett Syndrome

Recruiting
NCT00488072Phase 2

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Active Not Recruiting
NCT06684470Early Phase 1

Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator

Recruiting
NCT03852160Phase 3

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn
NCT06323837Phase 2

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

Recruiting
NCT05452174Phase 1

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

Withdrawn
NCT04446039

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed
NCT04614584Phase 1

Mirtazapine and Methamphetamine Drug-drug Interaction Study

Completed
NCT05170919Phase 2

Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

Enrolling By Invitation
NCT06309472Phase 2

Trial of Mirtazapine for Depression in IBD

Recruiting
NCT01240096Phase 4

Mirtazapine Versus Placebo in Functional Dyspepsia

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT05108688Phase 4

Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache

Completed
NCT03283488Phase 2

Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.

Completed
NCT04763135Phase 3

Mirtazapine in Cancer-related Poly-symptomatology

Terminated
NCT04728581Not Applicable

Improving Sleep After TKA Using Mirtazapine and Quetiapine

Not Yet Recruiting
NCT04748523Not Applicable

Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia

Completed
NCT03785691Phase 2

Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum

Terminated
NCT04155008Phase 4

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Terminated
NCT05380479Phase 2

Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients.

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
67